CD133 and CD166 Expression Predicting the Possibility of Prostatic Cancer Development in Cases of BPH

Khalida I. Noel^1*, Mustafa M. Ibraheem¹, Basim S. Ahmed², Ahmed F. Hameed¹, Nibras H. Khamees¹ and Sameh S. Akkila¹

¹Department of Human Anatomy, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

²Department of Pathology, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

Corresponding Author’s Email: dr.khalidanoel@uomustansiriyah.edu.iq

Abstract: Benign and malignant prostatic diseases are generally well-known in the world. Accordingly, this research is planned to assess the immunohistochemical analysis of CD133 and CD166 in the prostatic epithelium in samples of benign prostatic hyperplasia (BPH) and normal looking epithelium around prostatic adenocarcinoma samples (PCa) and to explore the opportunity of malignant alterations in benign tissue. The prostate samples were divided into 2 groups; 50 BPH samples, and 50 normally looking tissue surrounding prostatic carcinoma samples (NPCA). The samples were treated for immunohistochemical examination of CD133 and CD166. Over expression of CD133 appeared in the BPH group which was statistically significant as compared to NPCA group. Conversely, over expression of CD166 stem cell marker in NPCA group than BPH group as it was significant statistically. CD166 is a stem cell marker for tissue tumorigenicity, while the positive expression of CD133 is not of value for cancer initiation.

Keywords: BPH; CD133; CD166; Immunohistochemistry; Prostatic Cancer

[ HTML Full Text]

Back to TOC